^
    Back
    Association details:
    Biomarker:IFNG gene signature
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Clin Oncol
    Title:

    Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

    Excerpt:
    Exploratory analyses suggest that PD-L2 and IFN-γ signature may be associated with clinical response to pembro and may offer additional strategies to improve prediction of response.
    DOI:
    10.1200/JCO.2016.34.15_suppl.6010
    Trial ID:
    KEYNOTE-012